GSK agreed to acquire clinical-stage oncology company Nuvalent via an all-cash tender offer of $124.00 per share, ~$10.6 billion total (~$9.4 billion net of cash), announced June 9, 2026. The deal adds two late-stage, potential best-in-class next-generation selective tyrosine kinase inhibitors for non-small cell lung cancer: zidesamtinib (NVL-520, ROS1) and neladalkib (NVL-655, ALK). Both hold FDA Breakthrough Therapy and Orphan Drug designations and are under FDA review, with target action dates of 18 September 2026 (zidesamtinib) and 27 November 2026 (neladalkib). Expected to close in 2026.
Key facts
AnnouncedJun 09, 2026
Deal value$10.6B
Deal typeAcquisition/Merger
Therapeutic areaOncology (NSCLC)
IndicationsROS1-positive non-small cell lung cancer, ALK-positive non-small cell lung cancer